Navigation Links
MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device
Date:12/23/2009

ATLANTA, Dec. 23 /PRNewswire-FirstCall/ -- MiMedx Group, Inc. (OTC Bulletin Board: MDXG.OB) announced today that it has officially launched its first product, Paradis Vaso Shield(TM). In April 2009, The Food and Drug Administration cleared the Vaso Shield for use as a cover for vessels following anterior vertebral surgeries. The Vaso Shield is a permanent and transparent hydrogel product protected by multiple patents and patent applications, as well as a proprietary manufacturing process.

Upon completion of an anterior spinal implant procedure, the physician places the Vaso Shield between the spinal implant site and the vessels and then sutures it to the perivertebral, non-vascular soft tissue to secure the implant. The device is designed to protect the vessels in subsequent anterior revision surgeries.

The Company also announced the hiring of a Vice President of Sales and Marketing, Mr. Michael W. Carlton. Mr. Carlton brings an extensive background in the management of orthopedic and vascular implant sales and marketing. Mr. Carlton commented, "I am very impressed with MiMedx Group's two new biomaterials, namely its hydrogel and collagen fiber. These products have the potential to improve patient outcomes and significantly reduce costs. I look forward to joining this very experienced management team and assisting with the growth of MiMedx Group."

Parker H. "Pete" Petit, MiMedx Chairman and CEO, also commented, "This is an exciting day for MiMedx Group because it represents the commercialization of our first in a series of new products from our hydrogel material. With the hiring of Mike Carlton, we have added another experienced executive to our team. His expertise and leadership will be instrumental in developing our distribution network for our hydrogel spine products and for our future sports medicine collagen fiber products. We look forward to reporting the progress of our market acceptance and the growth of our revenues from Vaso Shield beginning in our first calendar quarter of 2010."

About MiMedx Group, Inc.

MiMedx Group, Inc. is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and is in the process of transitioning from a development-focused concern to an operating company focused on sales growth and profitability. The Company's assets include intellectual property protecting a collagen-based technology for augmentation of soft and connective tissue diseases and trauma and intellectual property protecting a novel durable hydrogel technology. The Company has received FDA clearance for its first durable hydrogel product, the Paradis Vaso Shield(TM), indicated for use as a cover for vessels following anterior spinal surgery.

Important Note regarding forward-looking statements and risk factors. This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those regarding the revenues from the Paradis Vaso Shield(TM) beginning in the first quarter of 2010, the growth of MiMedx Group, the prospects for receiving regulatory clearances or approvals for additional hydrogel or collagen fiber products and the development of a distribution network for the Company's products. These risks and uncertainties including, that the Company currently requires additional capital to survive and achieve its goals, which may be difficult or impossible to obtain, that the Company may not receive requisite regulatory clearances and/or approvals to be able to market a full range of products or that such clearances or approvals may be delayed, that the Company may not be able to establish an effective distribution system for its products, and that the Company's products may not gain acceptance in the marketplace or that acceptance may be delayed. The risks and uncertainties also include the risk factors detailed in its Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended March 31, 2009, and its most recent Form 10-Q filed on November 16, 2009. The Company does not undertake to update its forward-looking statements.

SOURCE MiMedx, Inc.


'/>"/>
SOURCE MiMedx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
3. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
4. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
5. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
6. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
7. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
8. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro)
11. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... May 27, 2016 According to ... hypertension is driving ambulatory blood pressure monitoring system market ... and their ability to respond to different pressure rates, ... can lead to various cardiovascular disorders such as heart ... These diseases are growing in prevalence each year. WHO ...
(Date:5/27/2016)... 27, 2016 Kitov ... focused on late-stage drug development, today announced the ... of pivotal batches required for registration of KIT-302 ... This follows Kitov,s announcement in December ... met its primary efficacy endpoint. "We ...
(Date:5/27/2016)... The healthcare sector is large ... all falling under its umbrella.  A rather overlooked sector ... talked about, these healthcare companies are still trying to ... is by far the largest consumer of the healthcare ... ADMD), Nutranomics Inc. (OTC: NNRX), KollagenX Corp. (OTCQB: KGNX), ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... , ... Psoriasis: Targets and Therapy has published ... author Professor Luigi Naldi says “The review in Psoriasis: Targets and Therapy throws ... onset and the severity of psoriasis, and negatively influences the response to systemic ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... individuals’ genetic characteristics and the physical and behavioral worlds in which they ... In personalized medicine, diagnosing an individual’s disease depends on accurately assessing his ...
(Date:5/31/2016)... ... May 31, 2016 , ... More than 80 representatives of the ... and the Prevent Cancer Foundation held an event on National Hepatitis Testing Day outside ... of viral hepatitis, the leading cause of liver cancer. , Foundation leaders and the ...
(Date:5/31/2016)... ... May 31, 2016 , ... Splashtop Inc., the worldwide leader in high ... Co., the leading provider of secure mobile remote access solution for Japan enterprises. ... CACHATTO remote access solution. Splashtop for CACHATTO will be available as an ...
(Date:5/31/2016)... ... ... Twenty years ago it was revolutionary: enabling the people who hear distressing voices to ... this approach has proven transformative, both for people who hear voices and for the ... used around the world, but it still lags in the United States. , Now, ...
Breaking Medicine News(10 mins):